AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16189291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 14767420 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal exercise at 2325 m above sea level
Number of subjects: 10
Study 14767420 — intervention group
Group type: COMPARATOR
Intervention: Submaximal exercise at 690 m above sea level
Number of subjects: 10
Study 14767420 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal exercise
Number of subjects: 10
Study 10942978 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 8621137 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography with Trucut needle
Number of subjects: 836
Study 8621137 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography with automatic biopsy needle
Number of subjects: 836
Study 8621137 — intervention group
Group type: COMPARATOR
Intervention: Trucut needle without ultrasonography
Number of subjects: 836
Study 8621137 — intervention group
Group type: COMPARATOR
Intervention: Automatic biopsy needle without ultrasonography
Number of subjects: 836
Study 8621137 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 836
Study 8621137 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic biopsy needle
Number of subjects: 836
Study 8621137 — intervention group
Group type: COMPARATOR
Intervention: Trucut needle
Number of subjects: 836
Study 1727581 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine PGF2 alpha infusion (20 mg diluted in 500 mL NaCl 0.9%)
Number of subjects: 22
Study 1727581 — intervention group
Group type: COMPARATOR
Intervention: IV oxytocin infusion (increasing doses)
Number of subjects: 22
Study 6690963 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroplasty plus diet
Number of subjects: 60
Study 6690963 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 60
Study 31133472 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit systolic BP variability
Number of subjects: 122
Study 31133472 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit diastolic BP variability
Number of subjects: 122
Study 31133472 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit pulse pressure variability
Number of subjects: 122
Study 26890999 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent Coping With Depression Course and Functional Family Therapy for SUD (depression treatment followed by SUD treatment)
Number of subjects: 170
Study 26890999 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent Coping With Depression Course and Functional Family Therapy for SUD (SUD treatment followed by depression treatment)
Number of subjects: 170
Study 26890999 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent Coping With Depression Course and Functional Family Therapy for SUD (coordinated treatment)
Number of subjects: 170
Study 26412509 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory Box (personalized multimedia device)
Number of subjects: 11
Study 24757032 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 physiotherapy booster sessions (30 minutes each)
Number of subjects: 78
Study 24757032 — intervention group
Group type: COMPARATOR
Intervention: No booster sessions (control)
Number of subjects: 78
Study 24757032 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster group
Number of subjects: 78
Study 24757032 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study 23019948 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing manipulation and joint regulation (Group 2)
Number of subjects: 20
Study 23019948 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing manipulation (Group 1)
Number of subjects: 20
Study 23019948 — intervention group
Group type: COMPARATOR
Intervention: Relaxing manipulation (normal group)
Number of subjects: 20
Study 20404423 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (100 mg/d)
Number of subjects: 40
Study 20404423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17692615 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.1 mg*kg‐1*min‐1)
Number of subjects: 40
Study 17692615 — intervention group
Group type: COMPARATOR
Intervention: Dopamine (3 mg*kg‐1*min‐1)
Number of subjects: 40
Study 15582638 — intervention group
Group type: EXPERIMENTAL
Intervention: Turning every 4 h on a viscoelastic foam (VE) mattress (n = 67)
Number of subjects: 838
Study 15582638 — intervention group
Group type: EXPERIMENTAL
Intervention: Turning every 2 h on a standard institutional (SI) mattress (n = 65)
Number of subjects: 838
Study 15582638 — intervention group
Group type: EXPERIMENTAL
Intervention: Turning every 3 h on a SI mattress (n = 65)
Number of subjects: 838
Study 15582638 — intervention group
Group type: EXPERIMENTAL
Intervention: Turning every 6 h on a VE mattress (n = 65)
Number of subjects: 838
Study 15582638 — intervention group
Group type: COMPARATOR
Intervention: Standard preventive care (n = 576)
Number of subjects: 838
Study 11933553 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-ventricular pacing mode
Number of subjects: 67
Study 11933553 — intervention group
Group type: COMPARATOR
Intervention: Inactive mode
Number of subjects: 67
Study 9785761 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (15 women) - daily outdoor walking and gymnastic training for 12 months
Number of subjects: 35
Study 9785761 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 women) - treated with calcium lactate and 1 alpha-hydroxyvitamin D3
Number of subjects: 35
Study 7710397 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute-phase ROP status between 32 and 42 weeks postconceptional age
Number of subjects: 4099
Study 7710397 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicatricial status at age 1 year
Number of subjects: 4099
Study 2744910 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbocysteine (4.5 g/day)
Number of subjects: 0
Study 2744910 — intervention group
Group type: COMPARATOR
Intervention: Glucose (placebo)
Number of subjects: 0
Study 341635 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 52
Study 341635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 6113175 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam (Noctamid) 1 mg
Number of subjects: 100
Study 6113175 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (Valium) 5 mg
Number of subjects: 100
Study 29994244 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed framework for visual representation and categorization
Number of subjects: 0
Study 29765200 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1981 (400 mg BID)
Number of subjects: 1140
Study 29765200 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1981 (other doses)
Number of subjects: 1140
Study 29765200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1140
Study 27391857 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynura pseudochina DC. var. hispida Thv. ointment
Number of subjects: 25
Study 27391857 — intervention group
Group type: COMPARATOR
Intervention: 0.1% triamcinolone (TA) cream
Number of subjects: 25
Study 24670946 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein and polydextrose (PPX) snack bar
Number of subjects: 10
Study 24670946 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic control snack bar
Number of subjects: 10
Study 21257799 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast (oral daily doses for 14 days)
Number of subjects: 16
Study 21257799 — intervention group
Group type: COMPARATOR
Intervention: Digoxin (single oral dose on day 1)
Number of subjects: 16
Study 21257799 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast and digoxin coadministration
Number of subjects: 16
Study 19171611 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based supervised therapy
Number of subjects: 290
Study 19171611 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 290
Study 17242947 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic absolute trial (HAT)
Number of subjects: 8
Study 17242947 — intervention group
Group type: COMPARATOR
Intervention: Control trial (CT)
Number of subjects: 8
Study 17242947 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic relative trial (HRT)
Number of subjects: 8
Study 15969659 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin challenge
Number of subjects: 117
Study 12043875 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated post and core permanently cemented
Number of subjects: 28
Study 9613305 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose regional labour analgesia (bupivacaine and fentanyl)
Number of subjects: 60
Study 9613305 — intervention group
Group type: COMPARATOR
Intervention: Spinal anaesthesia for elective Caesarean section
Number of subjects: 60
Study 7859894 — intervention group
Group type: EXPERIMENTAL
Intervention: Easiest mode of insulin injection
Number of subjects: 743
Study 7859894 — intervention group
Group type: COMPARATOR
Intervention: Two different forms of insulin delivery
Number of subjects: 743
Study 2510498 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (400 micrograms)
Number of subjects: 10
Study 2510498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 797259 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Number of subjects: 106
Study 797259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 31337414 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-way texting intervention (daily text messages with follow-up only if desired or if a complication is suspected)
Number of subjects: 722
Study 31337414 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 722
Study 29029606 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Care
Number of subjects: 131
Study 29029606 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual Care
Number of subjects: 131
Study 29029606 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Care
Number of subjects: 131
Study 29029606 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic-inclusive models (Shared Care and Dual Care)
Number of subjects: 131
Study 26143387 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (anxiety score ≤ 25)
Number of subjects: 109
Study 26143387 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (anxiety score > 25)
Number of subjects: 109
Study 26143387 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedure anxiety score > 25
Number of subjects: 109
Study 26143387 — intervention group
Group type: EXPERIMENTAL
Intervention: Male operator
Number of subjects: 109
Study 24423419 — intervention group
Group type: EXPERIMENTAL
Intervention: Fospropofol (initial dose of 6.5 mg/kg, supplemental doses of 1.6 mg/kg as needed)
Number of subjects: 60
Study 24423419 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (initial dose of 0.05 mg/kg, supplemental doses of 0.02 mg/kg)
Number of subjects: 60
Study 24423419 — intervention group
Group type: EXPERIMENTAL
Intervention: Fospropofol
Number of subjects: 60
Study 24423419 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 60
Study 24423419 — intervention group
Group type: EXPERIMENTAL
Intervention: Fospropofol and Midazolam
Number of subjects: 60
Study 21412134 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dexacort, 20 mg)
Number of subjects: 60
Study 21412134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19414694 — intervention group
Group type: EXPERIMENTAL
Intervention: DPTaP‐Hib vaccine first
Number of subjects: 120
Study 19414694 — intervention group
Group type: COMPARATOR
Intervention: PCV first
Number of subjects: 120
Study 17846346 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cardiotrophin-1 in patients with inappropriate left ventricular mass
Number of subjects: 118
Study 17846346 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cardiotrophin-1 after 1 year of antihypertensive treatment
Number of subjects: 118
Study 17846346 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of plasma cardiotrophin-1 with left ventricular mass
Number of subjects: 118
Study 15089810 — intervention group
Group type: EXPERIMENTAL
Intervention: Emfilermin (recombinant human leukaemia inhibitory factor, r-hLIF)
Number of subjects: 0
Study 10876462 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (40 mg)
Number of subjects: 30
Study 10876462 — intervention group
Group type: COMPARATOR
Intervention: Propofol (20 mg)
Number of subjects: 30
Study 9179056 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose chlorambucil (HD-CLB)
Number of subjects: 228
Study 9179056 — intervention group
Group type: COMPARATOR
Intervention: Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)
Number of subjects: 228
Study 1489115 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (1 mg/kg over 1 h)
Number of subjects: 8
Study 1489115 — intervention group
Group type: COMPARATOR
Intervention: Lateral position
Number of subjects: 8
Study 2951826 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ipratropium bromide (40 micrograms) and fenoterol (200 micrograms)
Number of subjects: 24
Study 2951826 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (200 micrograms)
Number of subjects: 24
Study 2951826 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 micrograms)
Number of subjects: 24
Study 2951826 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ipratropium bromide and fenoterol
Number of subjects: 24
Study 30112792 — intervention group
Group type: EXPERIMENTAL
Intervention: MYL-1501D
Number of subjects: 560
Study 30112792 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 560
Study 30112792 — intervention group
Group type: COMPARATOR
Intervention: MYL-1501D and Insulin glargine
Number of subjects: 560
Study 28231078 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise training (MIET) for 10 weeks (25-40 min/d, 3 d/wk at 50%-70% of heart rate reserve)
Number of subjects: 24
Study 28231078 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise training (MIET) for 10 weeks
Number of subjects: 24
Study 25779914 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck muscle vibration
Number of subjects: 45
Study 25779914 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery
Number of subjects: 45
Study 25779914 — intervention group
Group type: EXPERIMENTAL
Intervention: Action observation
Number of subjects: 45
Study 23535971 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion message
Number of subjects: 98
Study 23535971 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention message
Number of subjects: 98
Study 23535971 — intervention group
Group type: COMPARATOR
Intervention: Nonfit conditions
Number of subjects: 98
Study 21524790 — intervention group
Group type: COMPARATOR
Intervention: Cercon control (CC)
Number of subjects: 20
Study 21524790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cercon fatigue (CF)
Number of subjects: 20
Study 21524790 — intervention group
Group type: COMPARATOR
Intervention: Lava control (LC)
Number of subjects: 20
Study 21524790 — intervention group
Group type: EXPERIMENTAL
Intervention: Lava fatigue (LF)
Number of subjects: 20
Study 18065202 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone 40 mg once a day for 6 months
Number of subjects: 47
Study 18065202 — intervention group
Group type: COMPARATOR
Intervention: Casein placebo 40 mg once a day for 6 months
Number of subjects: 47
Study 16253974 — intervention group
Group type: EXPERIMENTAL
Intervention: Etonorgestrel
Number of subjects: 111
Study 16253974 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Number of subjects: 111
Study 14556479 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive and short duration chemotherapy (LMB protocols)
Number of subjects: 0
Study 10229288 — intervention group
Group type: COMPARATOR
Intervention: Depressed group (n = 9)
Number of subjects: 62
Study 10229288 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-depressed group (n = 53)
Number of subjects: 62
Study 9084317 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable membrane (Guidor USA)
Number of subjects: 8
Study 9084317 — intervention group
Group type: COMPARATOR
Intervention: Control (flap surgery alone)
Number of subjects: 8
Study 1906239 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP-144-SR 3.75 mg administered subcutaneously at 4-week intervals for 12 weeks (total of 3 injections)
Number of subjects: 134
Study 1906239 — intervention group
Group type: COMPARATOR
Intervention: Diethylstilbestrol diphosphate 100 mg administered orally three times a day for 12 weeks
Number of subjects: 134
Study 1906239 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP-144-SR
Number of subjects: 134
Study 1906239 — intervention group
Group type: COMPARATOR
Intervention: Diethylstilbestrol diphosphate
Number of subjects: 134
Study 6125155 — intervention group
Group type: EXPERIMENTAL
Intervention: estazolam (2 mg)
Number of subjects: 10
Study 6125155 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 31802455 — intervention group
Group type: EXPERIMENTAL
Intervention: TimeSlips intervention (one hour, once a week for six weeks)
Number of subjects: 20
Study 31802455 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal daily activities)
Number of subjects: 20
Study 31802455 — intervention group
Group type: EXPERIMENTAL
Intervention: TimeSlips intervention
Number of subjects: 20
Study 31802455 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 29238169 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of flupirtine maleate capsule under fasting condition
Number of subjects: 48
Study 29238169 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of flupirtine maleate capsule under fed condition
Number of subjects: 48
Study 29238169 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of flupirtine maleate capsule under fasting condition
Number of subjects: 48
Study 29238169 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of flupirtine maleate capsule under fed condition
Number of subjects: 48
Study 27798030 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) plus usual care
Number of subjects: 88
Study 27798030 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 88
Study 24929624 — intervention group
Group type: EXPERIMENTAL
Intervention: sitagliptin 100 mg/day
Number of subjects: 76
Study 22383949 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) administered for 60 days followed by placebo for another 60 days
Number of subjects: 0
Study 22383949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21158957 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Foods North (HFN) programme; a multi-institutional and culturally appropriate intervention to improve dietary adequacy and reduce chronic disease risk; specific dosage and duration not available.
Number of subjects: 0
Study 17685739 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (4800 mg/day)
Number of subjects: 40
Study 17685739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16351366 — intervention group
Group type: EXPERIMENTAL
Intervention: Deductive identity groups with depersonalization
Number of subjects: 0
Study 16351366 — intervention group
Group type: EXPERIMENTAL
Intervention: Inductive identity groups with depersonalization
Number of subjects: 0
Study 11909983 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonists
Number of subjects: 0
Study 11909983 — intervention group
Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 0
Study 9607010 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66
Number of subjects: 630
Study 9607010 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 630
Study 8550252 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 weeks of progressive resistive training
Number of subjects: 13
Study 8550252 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bout of resistive exercise
Number of subjects: 13
Study 2049711 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive awareness program plus bicycle helmet subsidy
Number of subjects: 0
Study 2049711 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive awareness program
Number of subjects: 0
Study 6133104 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (health education promoting a cholesterol-lowering diet, smoking cessation, weight control, physical activity, treatment of arterial hypertension)
Number of subjects: 19409
Study 6133104 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 19409
Study 31248399 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational leaflet
Number of subjects: 292
Study 31248399 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral presentation
Number of subjects: 292
Study 31248399 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 292
Study 30381311 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg once daily along with conventional management)
Number of subjects: 140
Study 30381311 — intervention group
Group type: COMPARATOR
Intervention: Conventional management for FGR
Number of subjects: 140
Study 25661322 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (25μg)
Number of subjects: 100
Study 25661322 — intervention group
Group type: COMPARATOR
Intervention: Foley catheter
Number of subjects: 100
Study 23738741 — intervention group
Group type: EXPERIMENTAL
Intervention: Health message condition
Number of subjects: 129
Study 23738741 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norm message condition
Number of subjects: 129
Study 23738741 — intervention group
Group type: COMPARATOR
Intervention: Control message condition
Number of subjects: 129
Study 21275439 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 50 mg on day 1, 100 mg on day 2, and 150 mg once daily on days 3 through 7
Number of subjects: 50
Study 21275439 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil
Number of subjects: 50